The earnings call reflected a generally positive outlook with significant advancements in Alzheimer's treatment development and strong financial positioning. However, the company reported a net loss for the quarter.

Company Guidance

During the Anavex Life Sciences Q4 2024 earnings call, several key metrics and updates were shared, particularly regarding their Alzheimer's treatment, blarcamesine. The European Medicines Agency (EMA) accepted the marketing authorization application for blarcamesine, supported by data from the Phase IIb/III ANAVEX-004 trial and its 144-week open-label extension, ATTENTION-AD. Financially, Anavex reported a cash position of $132.2 million as of September 30, 2024, with no debt, and a quarterly net loss of $11.6 million, or $0.14 per share. Research and development expenses were $11.6 million, while general and administrative expenses stood at $2.8 million. The company anticipates its current cash reserves will provide a runway of approximately four years. Additionally, Anavex plans to present top-line data from the ATTENTION-AD trial at the JPMorgan 2025 Healthcare Conference, further demonstrating their commitment to advancing innovative treatment options.

EMA Acceptance for Blarcamesine

The European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for blarcamesine for the treatment of Alzheimer's disease. This submission is backed by data from the Phase IIb/III ANAVEX-004 trial and a 144-week open-label extension entitled study ATTENTION-AD, potentially bringing the company closer to offering a new treatment option in Europe.

Upcoming Presentation at JPMorgan 2025 Healthcare Conference

Anavex announced its upcoming presentation of top line long-term data from the ATTENTION-AD open-label extension trial at the JPMorgan 2025 Healthcare Conference in January 2025.

Publication of Blarcamesine Data

A peer-reviewed manuscript titled blarcamesine for the treatment of early Alzheimer's disease from the ANAVEX2-73-AD-004 Phase II/III trial has been accepted for publication in a medical journal focused on Alzheimer's disease.

Encouraging Preliminary EEG Biomarker Results for ANAVEX 3-71

Anavex announced encouraging preliminary EEG biomarker results from Part A of the ongoing placebo-controlled Phase II clinical study of ANAVEX 3-71 for the treatment of schizophrenia, demonstrating a dose-dependent effect on two key EEG biomarkers.

Strong Financial Position

Anavex reported a cash position of $132.2 million with no debt, and a cash utilization rate indicating a runway of approximately 4 years.

---

Anavex Life Sciences (AVXL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AVXL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 09, 2018	2018 (Q3)	- / -0.06	-0.09	33.33% (+0.03)	―	―
Dec 12, 2018	2018 (Q4)	- / -0.13	-0.12	-8.33% (-0.01)	―	―
Feb 07, 2019	2019 (Q1)	- / -0.16	-0.09	-77.78% (-0.07)	―	―
May 08, 2019	2019 (Q2)	- / -0.17	-0.11	-54.55% (-0.06)	―	―
Aug 07, 2019	2019 (Q3)	- / -0.14	-0.06	-133.33% (-0.08)	―	―
Dec 16, 2019	2019 (Q4)	- / -0.07	-0.13	46.15% (+0.06)	―	―
Feb 06, 2020	2020 (Q1)	- / -0.12	-0.16	25.00% (+0.04)	―	―
May 07, 2020	2020 (Q2)	- / -0.12	-0.17	29.41% (+0.05)	―	―
Aug 06, 2020	2020 (Q3)	- / -0.11	-0.14	21.43% (+0.03)	―	―
Dec 28, 2020	2020 (Q4)	- / -0.10	-0.07	-42.86% (-0.03)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

AVXL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Dec 23, 2024	$8.63	$11.18	+29.55%
Aug 06, 2024	$6.45	$6.82	+5.74%
May 09, 2024	$3.71	$3.88	+4.58%
Feb 07, 2024	$5.79	$5.59	-3.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---